Basal cell carcinoma of the periocular region;Basalzellkarzinome des periokulären Bereichs

Pathologe

Volumn 34, Issue 6, 2013, Pages 552-557

  Geszti, F ^a   Hargitai, D ^a   Lukats O ^a   Gyorffy, H ^a   Toth J ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Aggressive growth; Extensive destruction; Histological subtypes; Recurrence rate; Resection borders

Indexed keywords

ARTICLE; BASAL CELL CARCINOMA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EYELID DISEASE; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; HUMAN; MULTIPLE CANCER; PATHOLOGY; PROGNOSIS; SKIN; SKIN TUMOR; TUMOR INVASION; TUMOR RECURRENCE;

CARCINOMA, BASAL CELL; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EYELID DISEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; SKIN; SKIN NEOPLASMS;

EID: 84888598255     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-013-1856-0     Document Type: Article

References (50)

1. Asada M, Schaart FM, Almeida HL de Jr et al (1993) Solid basal cell epithelioma (BCE) possibly originates from the outer root sheath of the hair follicle. Acta Derm Venereol 73:286-292
2. Auw-Haedrich C, Frick S, Boehringer D, Mittelviefhaus H (2009) Histologic safety margin in basal cell carcinoma of the eyelid: correlation with recurrence rate. Ophthalmology 116:802-806
3. Betti R, Radaelli G, Bombonato C et al (2010) Anatomic location of basal cell carcinomas may favor certain histologic subtypes. J Cutan Med Surg 14:298-302
4. Bolshakov S, Walker CM, Strom SS et al (2003) p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res 9:228-234
5. Carr RA, Sanders DSA (2007) Basaloid skin tumours: mimics of basal cell carcinoma. Curr Diag Pathol 13:273-300
6. Carr RA, Taibjee SM, Sanders DSA (2007) Basaloid skin tumours: basal cell carcinoma. Curr Diag Pathol 13:252-272
7. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ (2007) The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res 67:10511-10518
8. Chiu G, Thomson E, Woodwards R, Baldwin A (2011) Analysis of surgical clearence margins of head and neck basal cell carcinomas (BCC). Br J Oral Maxillofac Surg 49:1, 42
9. Cigna E, Tarallo M, Maruccia M et al (2011) Basal cell carcinoma: 10 years of experience. J Skin Cancer 2011:476362
10. Cook BE Jr, Bartley GB (1999) Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology 106:746-750
11. Cook BE Jr, Barttely GB (2001) Treatment options and future prospects for the management of eyelid malignancies: an evidence based update. Ophthalmology 108:2088-2098
12. Cretnik M, Poje G, Musani V et al (2009) Involvement of p16 and PTCH in pathogenesis of melanoma and basal cell carcinoma. Int J Oncol 34:1045-1050
13. Crowson AN (2006) Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 19(Suppl 2):S127- S147
14. Demirkesen C, Hoede N, Moll R (1995) Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeratins. J Cutan Pathol 22:518-535
15. Douki T, Reynaud-Angelin A, Cadet J, Sage E (2003) Bipyrimidine photoproducts rather than oxidative lesions are the main type of DNA damage involved in the genotoxic effect of solar UVA radiation. Biochemistry 42:9221-9226
16. Eshkoor SA, Ismail P, Rahman SA, Oshkour SA (2008) p16 gene expression in basal cell carcinoma. Arch Med Res 39:668-673
17. Fabricius EM, Bezeluk A, Kruse-Boitschenko U et al (2003) Clinical significance of telomerase activity in basal cell carcinomas and in tumour-free surgical margins. Int J Oncol 23:1389-1399
18. Fan YS, Carr RA, Sanders DS et al (2007) Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma. Histopathology 51:80-86
19. Haerslev T, Rossen K, Hou-Jensen K, Jacobsen GK (1995) Immunohistochemical detection of p53 in epidermal proliferations overlying dermatofibromas. Acta Derm Venereol 75:187-189
20. Heenan PJ, Bogle MS (1993) Eccrine differentiation in basal cell carcinoma. J Invest Dermatol 100:295S-299S
21. Howlader N, Noone AM, Krapcho M et al (2010) SEER Cancer Statistics Review, 1997/2001, National Cancer Institute. Bethesda, MD
22. Jacobs GH, Rippey JJ, Altini M (1982) Prediction of aggressive behaviour in basal cell carcinoma. Cancer 49:533-537
23. Józan P (1997) A nok egészségi á llapotának néhány jellemzoje. In: Lévai K, Tóth IG (Hrsg) Szerepváltozások. Jelentés a nok és férfiak helyzetérol. TÁRKI, Budapest, S 107-120
24. Kanellou P, Zaravinos A, Zioga M, Spandidos DA (2009) Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma. Br J Dermatol 160:1215-1221
25. Kanitakis J, Bourchany D, Claudy A (2000) Expression of the CD10 antigen (neural endopeptidase) by mesenchymal tumours of the skin. Anticancer Res 20:3539-3544
26. Karatas Silistreli O, Ayhan M, Aytug Z et al (2006) Periocular metatypical cell carcinoma: clinicopathologic correlation, management, and follow-up in 35 patients. J Plast Reconstr Aesthet Surg 59:1280-1287
27. Lovatt TJ, Lear JT, Bastrilles J et al (2005) Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. J Am Acad Dermatol 52:468-473
28. Lupi O (2007) Correlations between the sonic hedgehog pathway and basal cell carcinoma. Int J Dermatol 46:1113-1117
29. Malhotra R, Huilgol SC, Huynh NT, Selva D (2004) The Australian Mohs database, part I: periocular basal cell carcinoma experience over 7 years. Ophthalmology 111:624-630
30. Margo CE, Waltz K (1993) Basal cell carcinoma of the eyelid and periocular skin. Surv Ophthalmol 38:169-192
31. Martin RC 2nd, Edwards MJ, Cawte TG et al (2000) Basosquamous carcinoma: analysis of prognostic factors influencing recurrence. Cancer 88:1365-1369
32. McGregor JM, Yu CC, Dublin EA et al (1992) Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancer. Br J Dermatol 127:463-469
33. Moreno-Bueno G, Gamallo C, Perez-Gallego L et al (2001) β catenin expression in pilomatrixomas: relationship with β catenin gene mutations and comparison with β catenin expression in normal hair follicles. Br J Dermatol 145:576-581
34. Mosterd K, Krekels GA, Nieman FH et al (2008) Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 9:1149-1156
35. Nemet AY, Deckel Y, Martin PA et al (2006) Management of periocular basal and squamous cell carcinoma: a series of 485 cases. Am J Ophthalmol 142:293-297
36. Ouhtit A, Ananthaswamy HN (2001) A model for UV induction of skin cancer. J Biomed Biotechnol 1:5-6
37. Pinkus GS, Kurtin PJ (1985) Epithelial membrane antigen - a diagnostic discriminant in surgical pathology; immunohistochemical profile in epithelial, mesenchymal, and haemopoietic neoplasms using paraffin sections and monoclonal antibodies. Hum Pathol 16:929-940
38. Reifenberger J, Wolter M, Knobbe CB et al (2005) Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152:43-51
39. Rochette PJ, Brash DE (2010) Human telomeres are hypersensitive to UV-induced DNA damage and refractory to repair. PLoS Genet 6:e1000926
40. Sanders DSA, Carr RA (2007) The use of immunohistochemistry in the differential diagnosis of common epithelial tumours of the skin. Curr Diag Pathol 13:237-251
41. Scalvenzi M, Lembo S, Francia MG, Balato A (2008) Dermoscopic patterns of superficial basal cell carcinoma. Int J Dermatol 47:1015-1018
42. Smith V, Walton S (2011) Treatment of facial basal cell carcinoma: a review. J Skin Cancer 2011:380371
43. Soysal HG, Soysal E, Markoç F, Ardiç F (2008) Basal cell carcinoma of the eyelids and periorbital region in a Turkish population. Ophthal Plast Reconstr Surg 24:201-206
44. Spraul CW, Ahr WM, Lang GK (2000) Clinical and histologic features of 141 primary basal cell carcinomas of the periocular region and their rate of recurrence after surgical excision. Klin Monbl Augenheilkd 217:207-214
45. Svensson S, Nilsson K, Ringberg A, Landberg G (2003) Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res 63:1737-1742
46. Telfer NR, Colver GB, Morton CA (2008) Guidelines for the management of basal cell carcinoma. Br J Dermatol 159:35-48
47. Urosevic M, Oberholzer PA, Maier T et al (2004) Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Clin Cancer Res 10:4959-4970
48. Wetzig T, Maschke J, Kendler M, Simon JC (2009) Treatment of basal cell carcinoma. J Dtsch Dermatol Ges 7:1075-1082
49. Zagon IS, Verderame MF, McLaughlin PJ (2002) The biology of the opioid growth factor receptor (OGFR). Brain Res Brain Res Rev 38:351-376
50. Zghal M, Triki S, Elloumi-Jellouli A et al (2010) Contribution of the cryosurgery in the management of xeroderma pigmentosum. Ann Dermatol Venereol 137:605-609